NICE updates guidance on 7 DMARDS for rheumatoid arthritis
In final updated guidance NICE recommends a number of drugs (DMARDs) as options for treating severe rheumatoid arthritis which has not responded to intensive therapy with a combination of conventional DMARDs. The guidance does not recommend their use for treating moderate active rheumatoid arthritis. The guidance recommends Humira (adalimumab) from AbbVie, Enbrel (etanercept) from Pfizer, Remicade (infliximab) from Merck Sharp & Dohme; Inflectra, Hospira and Remsima from Napp Pharmaceuticals), Cimzia (certolizumab pegol) from UCB Pharma, Simponi (golimumab) from Merck Sharp & Dome, RoActemra (tocilizumab) from Roche and Orencia (abatacept) from Bristol-Myers Squibb, each in combination with methotrexate. Adalimumab, etanercept, certolizumab pegol or tocilizumab are also recommended as monotherapy for people who cannot take methotrexate.
Related news and insights
Medtronic announced the United States launch of the Penditure left atrial appendage (LAA) exclusion system, an implantable clip preloaded on a single-use delivery system for LAA management during concomitant cardiac surgery procedures
GSK plc announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma